Telomir Pharmaceuticals Inc. has secured $3 million in equity financing through a direct investment by The Bayshore Trust, the company's largest investor. The funding was raised via a straight equity sale at a premium, with no warrants involved, and is intended to support the advancement of its rare disease investigational new drug (IND) program. This financing extends Telomir's financial visibility by 12 months. Separately, Protagenic Therapeutics reported receiving $3.1 million from recent warrant activity.